Summit Therapeutics hits doable snag on lung most cancers drug seen as blockbuster
Summit Therapeutics could have a geography drawback with its lung most cancers drug ivonescimab.
In a examine replace reported Sunday, sufferers from North America and Europe handled with the drug noticed their lung most cancers return and progress quicker than sufferers from China — a discordant end result that might complicate Summit’s plans to safe approval of ivonescimab within the U.S. and Europe.
The chance of tumor development fell by 45% for members from China handled with ivonescimab and chemotherapy in comparison with chemotherapy and a placebo. For members from Western international locations, nonetheless, the chance of tumor development was diminished by 33% — an consequence that failed to achieve statistical significance.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
